投资者关系活动记录表 证券代码：300485 证券简称：赛升药业 北京赛升药业股份有限公司 投资者关系活动记录表 | --- | --- | --- | |------------------|---------------------------------|---------------------------------| | \n投资者关系活动 | 编号： 2015001 \n■ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 中邮基金 容杰 | | | 人员姓名 | 西南证券 何治力 | | | | 华商基金 张晓、陈恒 | | | | 中融人寿 汪虹、董凤亮 | | | | 银河证券 张金洋 | | | | 信达证券 李惜浣 | | | | 国寿安保基金 吴坚、王雪莹 | | | | 华夏基金 王泽实、张钧 | | | | 新华基金 潮礼君 | | 投资者关系活动记录表 | --- | --- | --- ...

投资者关系活动记录表 证券代码：300485 证券简称：赛升药业 北京赛升药业股份有限公司 投资者关系活动记录表 编号：2016001 | --- | --- | --- | |----------------|----------------------|------------------------------------------------| | | | | | | ■ | 特定对象调研 □分析师会议 | | 投资者关系活动 | □ | 媒体采访 □业绩说明会 | | 类别 | □ | 新闻发布会 □路演活动 | | | □ 现场参观 | | | | | □其他 （请文字说明其他活动内容） | | | | 华创证券：张文录、宋凯、王逸萌、刘宇腾、故宏亮 | | | 嘉实基金：颜媛 | | | | 东兴基金：邓巧 | | | | 泓德基金：操昭煦 | | | | 长盛基金：张伟光 | | | | 浦银安盛：刘诗瑶 | | | 参与单位名称及 | 江铜集团：邢连云 | | | 人员姓名 | 中融人寿：汪虹 | | | | 中国人寿资产：赵文龙 | | | | 天风证券：王卓、贾帅 | | | | 华融 ...

Financial Performance - Revenue for Q3 2022 was CNY 215,891,125.90, a decrease of 24.92% compared to the same period last year[3] - Net profit attributable to shareholders was CNY 18,443,537.92, down 64.79% year-on-year[3] - Basic earnings per share decreased by 63.64% to CNY 0.04[3] - The net profit for the third quarter of 2022 reached CNY 250,180,916.41, an increase of 88.17% compared to CNY 132,956,669.56 in the same period last year[10] - The total profit amounted to CNY 283,045,644.26, reflecting a growth of 79.19% from CNY 157,957,424.57 year-on-year[10] - The operating profit increased by 79.19% to CNY 283,067,954.35, driven by higher investment income from joint ventures and changes in the fair value of financial assets[10] - The company's basic earnings per share rose to CNY 0.52, marking a 79.31% increase from CNY 0.29 in the previous year[11] - Total operating revenue for the current period was ¥599,234,034.97, a decrease of 26.0% compared to ¥809,479,013.21 in the previous period[23] - Net profit for the current period was ¥250,180,916.41, an increase of 88.5% compared to ¥132,956,669.56 in the previous period[24] - The company reported a basic and diluted earnings per share of ¥0.52, up from ¥0.29 in the previous period[25] Assets and Equity - Total assets increased by 4.97% to CNY 3,570,725,389.62 compared to the end of the previous year[4] - Owner's equity attributable to shareholders rose by 5.40% to CNY 3,420,096,193.97[4] - Total assets rose to ¥3,570,725,389.62, compared to ¥3,401,649,422.52 in the previous period, reflecting a growth of 5.0%[21] - The company's total equity increased to ¥3,456,594,955.95 from ¥3,283,105,830.65 in the previous period[21] Cash Flow - Cash flow from operating activities for the year-to-date was CNY 90,144,873.36, down 28.47%[3] - Cash and cash equivalents at the end of the period decreased by 69.72% to CNY 119,581,121.81, attributed to a reduction in cash reserves[12] - The company's cash and cash equivalents decreased from CNY 161,543,438.37 at the beginning of the year to CNY 119,581,121.81 by September 30, 2022, a decline of approximately 26%[19] - The net cash flow from operating activities for the current period is ¥90,144,873.36, a decrease of 28.5% compared to ¥126,025,973.11 in the previous period[26] - Cash and cash equivalents at the end of the period amount to ¥119,581,121.81, down from ¥394,967,167.05 in the previous period[27] Investment and Expenses - Investment income increased by 208.29% to CNY 90,531,418.02, mainly due to higher equity method investment income[9] - Sales expenses decreased by 31.18% to CNY 294,296,573.46, attributed to reduced marketing activities[9] - Research and development expenses were ¥79,555,905.38, slightly down from ¥80,473,801.38 in the previous period[23] - The company achieved an investment income of ¥90,531,418.02, significantly up from ¥29,365,431.82 in the previous period[24] Inventory and Liabilities - Inventory decreased by 30.61% to CNY 85,392,157.97, primarily due to reduced raw material purchases[9] - The total current assets decreased from CNY 1,530,193,553.81 to CNY 1,464,545,372.82, a reduction of about 4.3%[19] - Total liabilities decreased to ¥114,130,433.67 from ¥118,543,591.87 in the previous period[21] Strategic Developments - The company established a venture capital fund with an investment of CNY 10 million, and acquired an 18% stake in Beijing Haijing Biomedical Technology Co., Ltd. for CNY 7.2 million[15] - The company signed a strategic cooperation framework agreement with Beijing Tianguangshi Biotechnology Co., Ltd. to enhance collaboration in drug development and production[16] - The subsidiary Junyuan Pharmaceutical obtained a drug production license from the Liaoning Provincial Drug Administration[16] - The company is currently conducting Phase I clinical trials for a humanized anti-VEGF monoclonal antibody injection, which is a key product under development[17] Other Financial Metrics - Non-recurring gains and losses totaled CNY 7,781,671.26 for the current period[6] - The income tax expense rose by 31.45% to CNY 32,864,727.85, driven by the increase in profits[10] - The total comprehensive income for the period was CNY 253,797,441.83, an increase of 91.17% compared to CNY 132,759,296.71 in the previous year[11] - The cash paid for purchasing goods and services decreased by 32.32% to CNY 84,357,054.43, reflecting a reduction in raw material procurement[11] - The company experienced a foreign exchange impact on cash and cash equivalents of ¥2,457,965.42, compared to -¥134,172.85 in the previous period[27] Shareholder Information - The total number of common shareholders at the end of the reporting period is 34,687[13] - The largest shareholder, Ma Jiao, holds 49.51% of the shares, totaling 238,464,000 shares[13] Audit Status - The company has not undergone an audit for the third quarter report[28]

北京赛升药业股份有限公司 2022 年半年度报告全文 北京赛升药业股份有限公司 2022 年半年度报告 2022-070 2022 年 8 月 1 北京赛升药业股份有限公司 2022 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人马骉、主管会计工作负责人马丽及会计机构负责人(会计主管 人员)栗建华声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本报告如有涉及未来计划等前瞻性陈述，均不构成公司对投资者的实质承 诺，投资者及相关人士均应当对此保持足够的风险认识，并且应当理解计划、 预测与承诺之间的差异。公司已在本报告"第三节管理层讨论与分析"之 "十、公司面临的风险和应对措施"部分，对可能面临的风险进行详细描述， 敬请投资者注意风险。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | 目录 | | --- | | 第一节 重要提示、目录和释义 | 2 | | --- | --- | | ...

北京赛升药业股份有限公司 2022 年第一季度报告全文 证券代码：300485 证券简称：赛升药业 公告编号：2022-042 北京赛升药业股份有限公司 2022 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保 证季度报告中财务信息的真实、准确、完整。 3.第一季度报告是否经过审计 □ 是 √ 否 (二)非经常性损益项目和金额 √ 适用 □ 不适用 单位：元 | 项目 | 本报告期金额 | 说明 | | --- | --- | --- | | 非流动资产处置损益（包括已计提资产减值准备的冲销部 | 2,718,143.33 | | | 分） | | | | 计入当期损益的政府补助（与公司正常经营业务密切相关， 符合国家政策规定、按照一定标准定额或定量持续享受的政 | 5,954,099.23 | | | 府补助 ...

Financial Performance - The company's operating revenue for the first half of 2021 was ¥521,930,586.60, representing a 7.72% increase compared to ¥484,520,630.90 in the same period last year[21]. - The net profit attributable to shareholders of the listed company was ¥85,333,463.28, a slight increase of 0.53% from ¥84,884,458.26 in the previous year[21]. - The net profit after deducting non-recurring gains and losses decreased by 32.89% to ¥51,614,391.46 from ¥76,915,530.41 in the same period last year[21]. - The net cash flow from operating activities was ¥82,364,563.18, down 42.08% from ¥142,201,118.48 in the previous year[21]. - The basic earnings per share remained unchanged at ¥0.18, consistent with the previous year[21]. - The diluted earnings per share also remained unchanged at ¥0.18, consistent with the previous year[21]. - The weighted average return on net assets was 3.01%, a decrease of 0.12% from 3.13% in the previous year[21]. - The total operating revenue for the first half of 2021 was CNY 521,930,586.60, an increase of 7.7% compared to CNY 484,520,630.90 in the first half of 2020[167]. - The company reported a net profit of 11,649,462.1 yuan for the first half of 2021, with total assets amounting to 22,608,698.7 yuan[89]. - The total comprehensive income for the first half of 2021 was CNY 81,788,656.96, compared to CNY 82,889,889.88 in the same period last year[169]. Assets and Liabilities - Total assets at the end of the reporting period were ¥3,026,206,534.72, an increase of 1.17% from ¥2,991,062,511.44 at the end of the previous year[21]. - The net assets attributable to shareholders of the listed company increased by 1.92% to ¥2,858,136,029.58 from ¥2,804,427,300.38 at the end of the previous year[21]. - The company's long-term equity investments increased to ¥468,016,729.95, accounting for 15.47% of total assets, up from 14.77% the previous year[57]. - Total liabilities decreased to CNY 125,784,628.92 from CNY 141,128,369.42, a reduction of about 10.9%[159]. - Owner's equity increased to CNY 2,900,421,905.80, up from CNY 2,849,934,142.02, representing a growth of approximately 1.8%[160]. - The cash and cash equivalents decreased significantly to CNY 376,546,597.51 from CNY 597,014,473.07, a decline of about 37.0%[162]. Research and Development - Research and development expenses surged by 125.08% to ¥56,488,696.35, reflecting the company's increased investment in ongoing research projects[50]. - The company is actively involved in the development of new products, including a recombinant shingles vaccine and a peptide drug for acute ischemic stroke[33]. - The company has established partnerships with several international medical system manufacturers for trade cooperation[32]. - The company has strengthened its R&D capabilities through partnerships with universities and research institutions, accelerating product development[43]. - The company has established a proprietary technology platform for the purification of biological macromolecules, which includes advanced techniques such as affinity chromatography and monoclonal antibody purification[46]. Market Position and Strategy - The company achieved over 50% market share in cardiovascular products and immunomodulators, establishing itself as a market leader[38]. - The sales model focuses on "on-site investment + academic promotion," with a distribution network targeting hospitals through distributors[36]. - The company is expected to maintain a significant market share in its immunomodulator products, particularly Thymosin Injection[38]. - The pharmaceutical industry in China has been experiencing continuous growth driven by increased medical demand and consumption upgrades[36]. - The company is exploring new investment opportunities to further strengthen its market position and financial performance[68]. Investment and Financial Management - The total amount of raised funds is CNY 1,080,944,700 after deducting issuance costs of CNY 72,855,300[75]. - Cumulative investment of raised funds reached CNY 708,010,000, with CNY 570,900,000 invested during the reporting period[74]. - The company invested CNY 463 million in bank wealth management products using raised funds, with a total of CNY 1.13 billion in wealth management products, and no overdue amounts reported[82]. - The company has made significant equity investments during the reporting period, including a long-term investment in Green Bamboo Bio-pharmaceutical Co., amounting to ¥20,000,000, representing a 9.82% stake[65]. - The company has not engaged in any derivative investments or entrusted loans during the reporting period[84][85]. Compliance and Governance - The company is committed to adhering to the disclosure requirements set by the Shenzhen Stock Exchange for pharmaceutical and biological products[38]. - The company has established robust internal control systems and external audits to ensure the safety of its overseas assets[58]. - The company has ensured timely, accurate, and complete disclosure of the use of raised funds, with no violations reported[79]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[103]. - The company has not engaged in any major litigation or arbitration matters during the reporting period[116]. Future Outlook - The company plans to focus on new product development and market expansion strategies in the upcoming quarters[184]. - The management expressed optimism about future growth prospects despite the current financial challenges[184]. - The company is exploring strategic acquisitions to enhance its competitive position in the market[192]. - The company plans to expand its market presence and invest in new product development to drive future growth[192].

北京赛升药业股份有限公司 2021 年第三季度报告 一、主要财务数据 证券代码：300485 证券简称：赛升药业 公告编号：2022-032 北京赛升药业股份有限公司 2021 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在 虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告 中财务信息的真实、准确、完整。 3.第三季度报告是否经过审计 □ 是 √ 否 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 本报告期比上年同期增 | | 年初至报告期末 | 年初至报告期末比上年 | | --- | --- | --- | --- | --- | --- | | | | 减 | | | 同期增减 | | 营业收入（元） | 342,775,244.87 | | 11.75% | 809,479,013 ...

北京赛升药业股份有限公司 2021 年第一季度报告全文 北京赛升药业股份有限公司 2021 年第一季度报告 2022-029 2022 年 03 月 1 第一节 重要提示 公司董事会、监事会及除以下存在异议声明的董事、监事、高级管理人员 外的其他董事、监事、高级管理人员均保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人马骉、主管会计工作负责人马丽及会计机构负责人(会计主管人 员)栗建华声明：保证季度报告中财务报表的真实、准确、完整。 2 北京赛升药业股份有限公司 2021 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 北京赛升药业股份有限公司 2021 年第一季度报告全文 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 233,134,003.59 | 167,249,354.70 | 39.39% | | 归属于上市公司股东 ...

Financial Performance - The company reported a profit distribution plan, proposing a cash dividend of 1.68 RMB per 10 shares based on a total of 481,666,400 shares[13]. - The company's operating revenue for 2021 was ¥1,050,805,089, a decrease of 3.97% compared to ¥1,094,225,280.40 in 2020[28]. - Net profit attributable to shareholders increased by 159.69% to ¥402,270,478.69 from ¥154,903,454.53 in the previous year[28]. - The net profit after deducting non-recurring gains and losses was ¥104,338,082.65, down 15.57% from ¥123,581,325.99 in 2020[28]. - The company's total assets increased by 13.73% to ¥3,401,649,422.52 at the end of 2021, compared to ¥2,991,062,511.44 at the end of 2020[28]. - Basic earnings per share rose by 162.50% to ¥0.84 from ¥0.32 in 2020[28]. - The company reported a net cash flow from operating activities of ¥183,295,288.13, a decrease of 30.50% from ¥263,725,621.99 in the previous year[28]. - The company reported non-recurring gains of ¥297,932,396.04 in 2021, significantly higher than ¥31,322,128.54 in 2020[34]. - The company achieved operating revenue of 1,050.81 million yuan, a decrease of 3.97% compared to the previous year, while net profit attributable to shareholders increased by 159.69% to 402.27 million yuan[59]. - The total revenue for the pharmaceutical manufacturing industry was approximately ¥1,049.66 million, accounting for 99.89% of total revenue, with a year-over-year decrease of 4.05%[76]. Research and Development - New drug development is a priority, but the company acknowledges the lengthy and uncertain nature of the process, which may impact operational costs and profitability[11]. - The company is focused on enhancing R&D capabilities and optimizing project selection to improve the success rate of new drug development[12]. - The company aims for an annual R&D investment growth of over 10% as part of its strategic goals during the "14th Five-Year Plan" period[38]. - The company emphasizes research and development, collaborating with academic institutions to accelerate product development[53]. - The company has established a proprietary biopharmaceutical purification technology platform, enhancing its production capabilities[54]. - The company has developed a key technology platform for antibody drugs, focusing on the discovery and research of new anti-tumor or immune-related antibodies[73]. - The company has established a platform for peptide drug design and synthesis, completing preliminary synthesis and process research for several anti-tumor drugs[73]. - The R&D department has filed 36 patents, with 17 patents granted during the reporting period[165]. - The management team emphasized a commitment to innovation, with a budget increase of 30% for R&D in 2022[166]. Market and Competition - The marketing network covers major cities in China, but the company anticipates challenges in market expansion due to evolving market demands and intensified competition[8]. - The company recognizes the potential for product price declines due to changes in procurement systems and increased competition in the market[9]. - The company is actively monitoring industry trends and may consider mergers or collaborations to achieve strategic goals[13]. - The company is focusing on internationalization in innovation, particularly in promoting traditional Chinese medicine abroad[38]. - The market for cardiovascular drugs is expected to expand due to an aging population, with projections indicating that by 2035, the population aged 65 and above in China will reach 210 million, accounting for 22.30% of the total population[42]. - The company is expanding its market presence through strategic partnerships and investments in biotechnology firms[53]. - The company is actively expanding its market presence through new product development and clinical trials, aiming to enhance its portfolio and revenue streams[72]. Product Development and Quality - The company emphasizes the importance of product quality, with a systematic quality control system in place to mitigate risks associated with complex production processes[10]. - The company is committed to increasing investment in product quality and accelerating the development of new products to meet regulatory requirements[10]. - The company has a diverse product pipeline with a balanced revenue contribution from various products, reducing reliance on any single product[53]. - The company focuses on the research, production, and sales of injectable drugs, with key products in cardiovascular, immune, and neurological disease treatments[43]. - The company has developed five national drug standard original research products, including fibrinolysin and its injection, and is the first in China to produce several key injectable drugs[44]. - The company’s immune regulation products include "Saiseng" and "Saisong" injections, targeting conditions such as progressive muscular dystrophy and chronic hepatitis[45]. - The company has completed the production registration application for a drug aimed at patients with bleeding tendencies, currently undergoing technical review[72]. - The company has prioritized rights for contract manufacturing and sales of BXOS110 project products post-approval, expanding its strategic development layout[68]. Governance and Management - The company has established a complete and independent financial management system, with dedicated accounting personnel and independent decision-making capabilities[146]. - The company ensures compliance with governance standards and has no significant discrepancies with regulatory requirements[143]. - The company has implemented performance evaluation and incentive mechanisms for senior management, ensuring transparency in appointments[142]. - The company actively engages with investors through various channels to enhance information transparency and investor relations[141]. - The board of directors consists of 8 members, including 3 independent directors, and held 13 meetings, reviewing 51 proposals[138]. - The company has expanded its board with independent directors who bring diverse expertise, including legal and financial backgrounds, to strengthen governance[158][159]. - The company has a clear focus on enhancing its market presence and operational efficiency through ongoing research and development initiatives[160]. Social Responsibility and Community Engagement - The company actively participated in social responsibility initiatives, donating a total of 100,000 RMB to aid flood relief efforts in Henan province[196]. - The company has established a partnership with Nanying Village in Pinggu District to support local economic development and poverty alleviation efforts[198]. - The company has implemented a GMP quality management system to ensure product quality and safety[196]. - The company has actively contributed to COVID-19 relief efforts by donating supplies to affected regions[196]. Strategic Investments and Acquisitions - The company has engaged in a merger and acquisition by acquiring a 3.077% stake in a biotechnology firm for ¥20,000,000[101]. - The company plans to focus on developing vaccines and treatments for various diseases through its recent acquisitions and investments[102]. - The company has completed two strategic acquisitions in the past year, enhancing its product portfolio and market reach[166]. - The company has signed a cooperation agreement with Lin Xuefang and Zhang Yi, indicating strategic partnerships for future growth[103]. Employee Development and Training - The company has implemented a flexible online training program for employees, including various training formats such as public courses and internal training[183]. - The company emphasizes the importance of talent development, implementing specific training plans for new graduates to ensure a strong talent pipeline for future growth[128]. - The total number of employees at the end of the reporting period is 584, with 447 in the parent company and 137 in major subsidiaries[180]. - The professional composition includes 172 production personnel, 82 sales personnel, 179 technical personnel, 14 financial personnel, and 137 administrative personnel[180].

Financial Performance - The company's revenue for Q3 2021 was CNY 342,775,244.87, an increase of 11.75% compared to the same period last year, and the year-to-date revenue reached CNY 1,212,681,679.32, up 53.26% year-on-year[3] - The net profit attributable to shareholders for Q3 2021 was CNY 52,379,695.74, representing an 18.33% increase year-on-year, while the year-to-date net profit was CNY 137,713,159.02, a 6.63% increase[3] - The basic earnings per share for Q3 2021 was CNY 0.11, up 22.22% year-on-year, and the diluted earnings per share was also CNY 0.11[4] - Total operating revenue for Q3 2021 reached CNY 1,212,681,679.32, a significant increase of 53.1% compared to CNY 791,257,671.76 in the same period last year[28] - Net profit for Q3 2021 was CNY 133,778,745.44, representing a 6.1% increase from CNY 126,247,006.57 in Q3 2020[29] - The company reported a total comprehensive income of CNY 133,581,372.59 for Q3 2021, up from CNY 126,247,006.57 in Q3 2020[31] Assets and Liabilities - The total assets as of September 30, 2021, were CNY 3,690,908,471.22, a 23.40% increase from the end of the previous year[4] - The total assets of the company as of Q3 2021 amounted to CNY 3,690,908,471.22, compared to CNY 2,991,062,511.44 at the end of Q3 2020, reflecting a growth of 23.4%[28] - The total liabilities increased to CNY 730,914,796.40, up from CNY 141,128,369.42, indicating a substantial rise in financial obligations[27] - The company's equity attributable to shareholders reached CNY 2,910,642,193.37, an increase from CNY 2,804,427,300.38 year-over-year[28] Cash Flow - The company's cash flow from operating activities for the year-to-date was CNY 82,079,575.10, down 63.72% compared to the same period last year[3] - The cash inflow from operating activities totaled CNY 1,150,837,917.77, an increase from CNY 891,367,653.51 in the previous period, representing a growth of approximately 29%[34] - The net cash flow from operating activities was CNY 82,079,575.10, down from CNY 226,249,463.81 in the previous period, indicating a decline of about 64%[34] - Cash outflow for purchasing goods and services was CNY 406,687,308.56, significantly higher than CNY 116,697,811.16 in the previous period[34] - The net cash flow from investing activities was negative at CNY -273,881,865.82, an improvement from CNY -530,418,724.81 in the previous period[35] - The company reported a cash outflow of CNY 36,152,698.13 from financing activities, compared to CNY 31,456,497.57 in the previous period, indicating a higher cash outflow[35] Research and Development - Research and development expenses for the year-to-date were CNY 80,473,801.38, an increase of 88.25% year-on-year, indicating a significant investment in R&D[12] - Research and development expenses increased to CNY 80,473,801.38, up 88.5% from CNY 42,749,087.53 in the previous year[29] Receivables and Liabilities - The company reported an increase in trading financial assets by 68.83% year-to-date, reaching CNY 857,121,656.75, due to increased short-term bank investment[8] - The company's accounts receivable increased by 53.10% year-to-date, amounting to CNY 176,394,679.01, primarily due to receivables from a consolidated subsidiary[8] - The company experienced a significant increase in contract liabilities, which rose by 3778.67% year-to-date to CNY 419,956,003.18, mainly from a consolidated subsidiary[10] Investment Income - The investment income for the year-to-date was CNY 28,692,824.28, a 162.72% increase year-on-year, driven by gains from stock sales and investment returns[13] - Cash received from investment income was 31,645,831.76 CNY, an increase of 19,405,691.44 CNY or 158.54% year-over-year, mainly from the sale of part of the company's holdings in Kang Le Wei Shi stocks and increased financial income[16] - Cash paid for investments was 81,000,000.00 CNY, an increase of 28,848,240.00 CNY or 55.32% year-over-year, indicating increased external investments[17] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 34,327, with the largest shareholder holding 49.51% of the shares[20] Other Financial Information - The company received CNY 28,790,292.71 in tax refunds during the period[34] - The company did not adjust the beginning balance sheet items for the new leasing standards as there were no related leasing activities[36] - The third quarter report was not audited[36]